TerminatedPhase 3NCT03041116
Efficacy and Safety Study of Fosmetpantotenate (RE-024) in PKAN Participants
Studying Pantothenate kinase-associated neurodegeneration
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Travere Therapeutics, Inc.
- Principal Investigator
- Thomas Klopstock, MDKlinikum der Universität München
- Intervention
- Fosmetpantotenate(drug)
- Enrollment
- 84 enrolled
- Eligibility
- 6-65 years · All sexes
- Timeline
- 2017 – 2019
Study locations (19)
- Travere Investigational Site, Irvine, California, United States
- Travere Investigational Site, Washington D.C., District of Columbia, United States
- Travere Investigational Site, Miami, Florida, United States
- Travere Investigational Site, Decatur, Georgia, United States
- Travere Investigational Site, Chicago, Illinois, United States
- Travere Investigational Site, Boston, Massachusetts, United States
- Travere Investigational Site, New York, New York, United States
- Travere Investigational Site, Pittsburgh, Pennsylvania, United States
- Travere Investigational Site, Houston, Texas, United States
- Travere Investigational Site, Toronto, Ontario, Canada
- Travere Investigational Site, Prague, NAP, Czechia
- Travere Investigational Site, Montpellier, Languedoc-Rousillon, France
- Travere Investigational Site, Paris, Île-de-France Region, France
- Travere Investigational Site, München, Bavaria, Germany
- Travere Investigational Site, Milan, Italy
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03041116 on ClinicalTrials.gov